(3-phenylpropyl)piperazine; RTI-229, 3ß-(4-iodophenyl)tropane-2ß-pyrrolidine carboxamide tartrate; BSA, bovine serum album; HPLC-EC, high performance liquid chromatography with electrochemical detection. ANOVA, analysis of variance.
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The search for effective appetite suppressants is underscored by the continuing problem of obesity and its associated medical complications. (±)-Fenfluramine (Pondimin TM ) and its more potent stereoisomer, (+)-fenfluramine (dexfenfluramine, Redux TM ), are anorectic agents that were widely prescribed until their removal from the market due to adverse effects (Connolly and McGoon, 1999) . Even though fenfluramines are no longer clinically available, the mechanisms responsible for their powerful anorectic actions are of great interest. Pharmacokinetic investigations have
shown that stereoisomers of (±)-fenfluramine are N-de-ethylated by liver enzymes to yield the metabolites, (+)-and (-)-norfenfluramine (Caccia et al., 1985) . In humans and animals receiving systemic (±)-fenfluramine, circulating concentrations of (+)-and (-)-norfenfluramine are similar to or greater than concentrations of fenfluramine itself (Marchant et al., 1992) . Moreover, stereoisomers of (±)-fenfluramine and (±) norfenfluramine cross the blood-brain barrier to accumulate in the central nervous system (CNS). Thus, peripheral administration of (±)-fenfluramine gives rise to four pharmacological agents with potential neurobiological activity.
Historical evidence shows that stereoisomers of (±)-fenfluramine stimulate serotonin (5-HT) transmission (Pinder et al., 1975) . Specifically, these agents increase synaptic and extrasynaptic levels of 5-HT in nervous tissue by a mechanism involving 5-HT transporter proteins (SERTs) (Rothman and Baumann, 2002) . Drugs that interact with SERTs, or other membrane-bound transporter proteins, can be divided into two classes: uptake inhibitors and substrate-type releasers. Uptake inhibitors bind to transporter proteins but are not transported. These drugs increase extracellular concentrations of neurotransmitters by interfering with neurotransmitter recapture from
the synaptic cleft. Substrates, in contrast, are transported into the nerve terminal where they promote the release of intracellular neurotransmitters by a process of carriermediated exchange (Rudnick and Clark, 1993) . Most findings indicate that stereoisomers of (±)-fenfluramine and (±)-norfenfluramine increase extracellular 5-HT by acting as substrates for SERTs (for review see Garattini et al., 1986) . Recent in vivo microdialysis studies confirm that 5-HT release evoked by (±)-fenfluramine or (+)-fenfluramine is antagonized by pretreatment with the SERT inhibitor fluoxetine (Prozac TM ) (Gundlah et al., 1997; Tao et al., 2002) .
In our laboratory, we have developed a high-throughput in vitro method that can be used to discriminate between drugs that act as transporter uptake inhibitors versus substrate-type releasers. Using this method, it is possible to profile the mechanism of action of test drugs at norepinephrine (NE) transporters (NETs), dopamine (DA) transporters (DATs), and SERTs using nearly identical assay conditions ). With few exceptions (Pettersson, 1995; Cozzi et al., 1998) , investigations examining the neuropharmacology of fenfluramines and norfenfluramines have focused on the 5-HT effects of these drugs (for review see Garattini et al., 1986) . For this reason, we studied the interaction of (±)-fenfluramine, (±) Rothman et al., 2001 CMA/Microdialysis, Acton, MA) were implanted into the frontal cortex according to the following coordinates (ML -2.5mm and AP +3.0mm from bregma, DV -0.8mm from dura). The guide cannulae were secured to the skull using stainless steel screws and dental acrylic. Animals were housed individually and allowed 7-10 days for recovery.
In Vivo Microdialysis. Microdialysis sampling was carried out as previously described with minor modifications ). On the evening before an experiment, rats were moved to the testing room and lightly anesthetized with methohexitol (5 mg/kg, i.v.). While anesthetized, a tether collar was placed on each rat. A microdialysis probe with a 3 x 0.5 mm exchange surface (CMA/12, CMA/Microdialysis) was lowered into the guide cannula and an extension tube was attached to the jugular catheter. Each rat was placed into its own plastic container and connected to the tethering system that allowed motor activity within the container. The microdialysis solution containing 150.0 mM Na, 3.0 mM K, 1.4 mM Ca, 0.8 mM Mg, 1.0 mM P, and 155 mM Cl (Harvard Bioscience, Holliston, MA) was pumped through the probe overnight at 0.5 µl/min. On the next morning, the flow rate was increased to 1.1 µl/min and dialysate samples were collected at 20-min intervals. Samples were split so that 10 µl were assayed for DA and 5-HT, and 10 µl were assayed for NE by high pressureliquid chromatography with electrochemical detection (HPLC-EC) as described below.
When three stable baseline samples were obtained, drug treatments were administered. Software, Bethesda, MD) as described elsewhere (Rothman et al., 1993) . Ki values were calculated from uptake assay results according to the formula:
Analysis of
where L is the concentration of the radiolabeled drug ([ Table 1 , (±)-fenfluramine and its stereoisomers were essentially inactive in the DA release assay. The most potent action of (±)-fenfluramine and its stereoisomers was to evoke [
Results

As reported in
Results obtained in the uptake inhibition assays paralleled the results of the release assays, and these findings are summarized in Table 2 . In general, as observed with other transporter substrates , the substrates tested here were more potent in the release assays than in the uptake inhibition assays.
Substrate reversal experiments were performed to determine the role of SERT and NET in mediating the neurotransmitter releasing activity of (±)-fenfluramine, (± The data in Figure 7 depict the effects of nisoxetine pretreatment on transmitter release evoked by (+)-norfenfluramine, when peak effects of (+)-norfenfluramine are calculated a percent of pre-existing baseline. The dialysis data from Figures 5 and 6
were used to calculate means as follows: transmitter level at 80 min (peak effect of acute drug or saline) divided by transmitter level at 60 min (immediately before acute challenge) times 100. Stated more simply, the data in Figure 7 are expressed to factor out the effect of nisoxetine alone. When the data are normalized in this manner, it is apparent that nisoxetine significantly blunts the maximal effect of (+)-norfenfluramine on NE and DA release (P<0.05, Duncans'), but not 5-HT release.
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Discussion
The main goal of the present study was to assess the activity of stereoisomers of (±)-fenfluramine and (±)-norfenfluramine at monoamine transporters. Our in vitro results confirm that these drugs stimulate 5-HT release by a mechanism involving SERT proteins (Garattini, 1995; Rothman and Baumann, 2002) . ( The fact that (+)-isomers of fenfluramine and norfenfluramine are able to elevate extracellular DA in vivo is surprising based on the low potency of these drugs as DA releasers in vitro (see Table 1 ). One possibility is that NET sites are involved in the DA extracellular medium into cells via either transporter ). Indeed, NETs contribute significantly to the neuronal uptake of DA in rat cortex, a region where the density of NET sites is greater than that of DAT sites (Carboni et al., 1990; Tanda et al., 1997; Linner et al., 2001) . Our microdialysis results show that blockade of NE uptake with nisoxetine increases extracellular DA along with NE, suggesting NE nerve terminals in rat frontal cortex might contain both DA and NE. Consistent with this notion, (+)-norfenfluramine released DA and NE to a similar extent. The ability of (+)-norfenfluramine to evoke in vivo release of NE and DA was partially antagonized by nisoxetine, indicating that NETs play at least some role in the catecholamine-releasing activity of (+)-norfenfluramine ( Figure 7 ).
Chronic administration of (±)-fenfluramine or (+)-fenfluramine to humans leads to steady state plasma levels of (±)-norfenfluramine and (+)-norfenfluramine that are about one half the plasma levels of parent drugs (Caccia et al., 1985) . In nonhuman primates, plasma levels of (+)-norfenfluramine exceed those of the parent drug by more than 10-fold due to rapid elimination of (+)-fenfluramine in these species. In rats, circulating levels of (+)-norfenfluramine can surpass those of (+)-fenfluramine for hours after peripheral administration of (+)-fenfluramine (De Souza et al., 1991) . Importantly, Clinical pharmacokinetic studies indicate that anorectic doses of (+)-fenfluramine produce brain concentrations of (+)-norfenfluramine high enough to elicit NE release.
For example, Christensen and coworkers (Christensen et al., 1999) used 19 F magnetic resonance spectroscopy to measure steady state levels of (+)-fenfluramine and (+)-norfenfluramine in plasma and brain tissue of human subjects. These investigators reported that daily oral administration of 30 mg (+)-fenfluramine produced a combined concentration of (+)-fenfluramine and (+)-norfenfluramine of about 4 µM in the brain.
Given that plasma (+)-norfenfluramine concentrations are approximately one half those of (+)-fenfluramine (Caccia et al., 1985) , brain levels of (+)-norfenfluramine are likely to be in the range of 1 µM, a concentration that is sufficient to release NE.
The collective findings suggest that NE mechanisms might be involved in mediating pharmacological actions of fenfluramines. As noted in the Introduction, (±)-fenfluramine and (+)-fenfluramine are effective appetite suppressants, and anorectic effects of the drugs are presumably related to stimulation of 5-HT transmission in the CNS (Pinder et al., 1975; Garattini et al., 1986) . However, emerging evidence indicates that 5-HT release per se is not required for fenfluramine-induced anorexia (Curzon et al., 1997) . For example, certain pharmacological manipulations which completely block fenfluramine-evoked 5-HT release do not alter hypophagic effects of the drug (Gibson et al., 1993; Raiteri et al., 1995) . Such observations have fueled speculation that (±)-fenfluramine and (+)-fenfluramine produce their anorectic effects via direct activation of 5-HT 2C receptor sites. Table 3 at 5-HT 2C receptors (Rothman et al., 2000) . In the present study, (+)-fenfluramine and Probably the strongest evidence for a physiologically relevant noradrenergic effect of fenfluramine comes from studies examining renin secretion. Activation of the sympathetic nervous system increases the secretion of renin from the kidneys (Cody, 1997) . Conversely, suppression of sympathetic nervous activity via stimulation of central alpha 2 adrenergic receptors decreases renin secretion (Oates et al., 1978; Schoeppe and Brecht, 1980) . In rats, administration of (±)-fenfluramine produces an initial stimulation of renin secretion that is mediated by 5-HT release, followed by a long-lasting inhibition of renin secretion that is mediated by central NE nerves (Van de Kar et al., 1994) . Administration of the NE uptake blocker, desipramine, completely abolishes the delayed suppression of renin release produced by (±)-fenfluramine (Van de Kar et al., 1994) . Based on the present findings, it seems likely that (±)-fenfluramine administration leads to the formation of (+)-norfenfluramine, which then acts as a substrate for NETs in the brain. The ensuing elevations in extracellular NE stimulate alpha 2 receptors to decrease sympathetic outflow and renin secretion.
This article has not been copyedited and formatted. The final version may differ from this version. Clinical studies provide further support for the importance of NE mechanisms in mediating fenfluramine-induced inhibition of renin secretion. In humans, (+)-fenfluramine decreases sympathetic nervous system activity (Hirsch et al., 2000) , plasma NE (Andersson et al., 1991; Kolanowski et al., 1992; Flechtner-Mors et al., 1998) , blood pressure (Andersson et al., 1991; Kolanowski et al., 1992; Flechtner-Mors et al., 1998) , and plasma renin (Andersson et al., 1991) . Interestingly, administration of the 5-HT precursor, 5-hydroxytryptophan, causes cardiovascular effects similar to (+)-fenfluramine but does not decrease plasma renin (Maestri et al., 1988) . Thus, two agents that produce comparable increases in synaptic 5-HT differ with respect to their effects on plasma renin. One reason for this discrepancy might be related to NE release associated with the formation of (+)-norfenfluramine after systemic (+)-fenfluramine. It is noteworthy that amphetamine releases NE from neurons and increases blood pressure (Weiner, 1989) . The fact that (±)-fenfluramine, which releases NE via its metabolite (±)-norfenfluramine, does not increase blood pressure is probably because rapid and simultaneous elevations of synaptic 5-HT produce an overall reduction in blood pressure (Zimmermann and Ganong, 1980; Ramirez et al., 1982; Itskovitz et al., 1989) .
Viewed collectively, the present results emphasize the complex pharmacology of (±)-fenfluramine. From a pharmacokinetic perspective, administration of (±)-fenfluramine generates four bioactive agents: (+)-fenfluramine, (-)-fenfluramine, (+)-norfenfluramine and (-)-norfenfluramine. These compounds interact to varying degrees with SERTs, NETs, and multiple 5-HT 2 receptor subtypes. We have previously proposed that substrate activity at SERTs is one factor responsible for the increased incidence of primary pulmonary hypertension in patients who have taken fenfluramines (Rothman et al., 1999) . As discussed above, activation of 5-HT 2C receptors is thought to mediate the anorectic effects of fenfluramines, and (+)-norfenfluramine is probably involved in this effect due to its potent affinity for 5-HT 2C receptors (Garattini, 1995; Curzon et al., 1997; Vickers et al., 2001) . Accumulating evidence shows that activation of 5-HT 2B receptors underlies cardiac valve disease associated with (±)-fenfluramine and (+)-fenfluramine (Fitzgerald et al., 2000; Rothman et al., 2000) and also might contribute to the development of pulmonary hypertension (Launay et al., 2002) ; in this case, (+)-norfenfluramine is a likely culprit based on its potent activity at 5-HT 2B sites.
Further research is warranted to assess the precise role of NE in mediating the diverse pharmacological actions of fenfluramines.
